Metabolic Cut – Start
The Metabolic Cut – Start is a focused three-part metabolic research stack. It pairs a next-generation GLP receptor agonist with the NNMT-modulator 5-Amino-1MQ and the injectable exercise-mimetic SLU-PP-332.
Curated for laboratory study of appetite signaling, basal metabolic rate and cellular energy expenditure – three complementary research compounds in one set, bundled below their combined individual price.
Original price was: 346,00 €.294,00 €Current price is: 294,00 €.
A curated 3-part metabolic research stack: a next-generation GLP receptor agonist, 5-Amino-1MQ and injectable SLU-PP-332.
What's included in this stack
Metabolic Cut - Start - Focused Three-Compound Metabolic Research Stack
Description
Mechanism of Action
This research bundle is designed to investigate a multi-pathway approach to metabolic regulation. GLP-3R (Rеtаtrutіdе) is studied for systemic glucose and appetite signaling via triple GLP-1/GIP/glucagon receptor agonism, while 5-Amino-1MQ is investigated for its role in cellular energy and fat metabolism through potential NNMT inhibition. The injectable ERR agonist Slu-pp-332 is studied in parallel for its influence on mitochondrial biogenesis and oxidative metabolism, together exploring complementary effects on energy expenditure and body composition in research models.
Benefits
- Triple Metabolic Agonism – Rеtаtrutіdе is investigated for its multi-pathway activation of energy metabolism, enhancing insulin secretion, suppressing appetite, and promoting lipid oxidation.
- Targeted Fat Reduction – The stack is researched for its ability to significantly reduce visceral and hepatic fat accumulation, with compounds like Rеtаtrutіdе and 5-Amino-1MQ promoting lipid oxidation and reduced adiposity.
- Increased Energy Expenditure – The stack is investigated for its capacity to increase whole-body metabolic rate and thermogenic activity, with compounds like Rеtаtrutіdе and 5-Amino-1MQ enhancing mitochondrial respiration.
- Optimized Glucose Control – The stack is studied for its ability to enhance insulin secretion and sensitivity, improving peripheral glucose uptake and overall glycemic control.
- Mitochondrial Biogenesis – Slu-pp-332 and 5-Amino-1MQ are investigated for their roles in stimulating new mitochondrial creation and improving cellular respiration, supporting enhanced energy efficiency.
- Lean Mass Preservation – The stack is studied for its support in maintaining lean muscle tissue during periods of significant fat loss and metabolic optimization.
- Reduced Systemic Inflammation – The stack is researched for its capacity to reduce inflammatory cytokines and improve antioxidant defenses, supporting overall metabolic health and tissue protection.
- Improved Muscle Endurance – Slu-pp-332 is investigated for its ability to improve exercise performance by upregulating oxidative muscle fibers and enhancing fatigue resistance.
Research Data
GLP-2T
| Study / Model | Reported effect |
| Human clinical trials (SURPASS program, T2DM) | ↓ HbA1c (up to -2.4%) and body weight (-12 kg over 40 weeks) vs insulin and Sеmаglutіdе. |
| Human clinical trials (obesity without diabetes) | 15-22% mean weight loss at 72 weeks; improved lipids and blood pressure. |
| Comparative RCTs (Tіrzеpаtіdе vs Sеmаglutіdе) | Higher efficacy in weight and glycemic outcomes; similar tolerability. |
| NAFLD / NASH models | ↓ hepatic steatosis and transaminases (ALT/AST); improved insulin response and mitochondrial function. |
| GLP-1/GIP receptor studies (preclinical) | Dual receptor activation → ↑ insulin secretion, ↓ appetite, ↑ energy efficiency. |
| Cardiometabolic outcomes (post-hoc human) | ↓ total cholesterol, LDL, triglycerides, CRP; improved insulin sensitivity. |
| Animal obesity / high-fat diet models | ↓ fat mass, ↑ thermogenesis and glucose tolerance. |
| Human tolerability studies (Phases 1-3) | Common mild effects: nausea, diarrhea; no serious hepatic or hematologic effects. |
| Long-term weight maintenance (extension trials) | >80% of weight reduction maintained after 88 weeks of continued use. |
5-Amino-1MQ
| Study / Model | Reported effect |
| Diet-induced obese mice (DIO model) | ↓ body weight by 40%, ↓ fat mass, ↑ lean mass without caloric restriction. |
| NNMT knockout comparison | Mimicked genetic NNMT deletion benefits: ↑ NAD+, ↑ SIRT1, ↑ mitochondrial respiration. |
| In vitro adipocyte culture | ↓ lipid accumulation, ↑ AMPK activation, ↓ inflammatory cytokines. |
| High-fat diet mouse study | ↓ fasting glucose and insulin levels, improved insulin tolerance. |
| Liver steatosis models | ↓ hepatic triglycerides and lipid deposition; ↑ mitochondrial biogenesis. |
| Combination NAD+ + 5-Amino-1MQ | Synergistic NAD+ increase and enhanced metabolic flexibility. |
| Neuroinflammation model | ↓ ROS generation, ↑ mitochondrial membrane potential in neuronal cells. |
Slu-pp-332 Capsules
| Research Area | Model / Setting | Reported Observation |
|---|---|---|
| Mitochondrial biogenesis | Rodent skeletal muscle | Increased mitochondrial density via ERR activation |
| Endurance capacity | Treadmill running models | Enhanced running distance and fatigue resistance reported |
| Energy metabolism | Diet-induced obesity mice | Reduced fat accumulation and increased energy expenditure |
| Lipid oxidation | Cell and animal studies | Upregulated fatty-acid oxidation pathways |
| Receptor pharmacology | In vitro ERR assays | Pan-agonist activity across ERRα, ERRβ and ERRγ |
Data above is summarised from preclinical and in-vitro literature and is provided for research orientation only. It does not constitute clinical evidence of efficacy in humans.
Stack Suggestions
This research bundle is suited for investigators exploring entry-level multi-pathway metabolic interventions, particularly the interplay between systemic incretin signaling, cellular energy metabolism and mitochondrial biogenesis on body composition and glucose homeostasis.
Pen Dosage Chart
GLP-2T
| GLP-2T Pen 5 mg | |
|---|---|
| Volume | 1.5 mL |
| mg/mL | 3.333 mg/mL |
| Click-to-Dose | 1 click = 0.033 mg |
| Example(s) | 10 clicks = 0.333 mg |
| GLP-2T Pen 10 mg | |
|---|---|
| Volume | 1 mL |
| mg/mL | 10 mg/mL |
| Click-to-Dose | 1 click = 0.1 mg |
| Example(s) | 10 clicks = 1 mg |
| GLP-2T Pen 15 mg | |
|---|---|
| Volume | 1.5 mL |
| mg/mL | 10 mg/mL |
| Click-to-Dose | 1 click = 0.1 mg |
| Example(s) | 10 clicks = 1 mg |
5-Amino-1MQ
| 5-Amino-1MQ Pen 100 mg | |
| Volume | 3.0 mL |
| mg/mL | 33.33 mg/mL |
| Click-to-Dose | 1 click = 0.33 mg |
| Example(s) | 15 clicks = 5 mg |
Slu-pp-332 Capsules
| Slu-pp-332 Capsules – 300 mcg | |
| Strength | 300 mcg (0.3 mg) per capsule |
| Bottle sizes | 30 or 60 capsules |
| Standard serving | 1 capsule once daily |
| Total content | 9 mg (30 capsules) / 18 mg (60 capsules) |
Dosage & Protocols Variations
GLP-2T
Standard Research Protocol
- Dose: 2.5 – 5 mg (variant 5 mg pen = 76–152 clicks / variant 10 mg pen = 25–50 clicks / variant 15 mg pen = 25–50 clicks)
- Duration: 8 – 12 weeks
- Frequency: 1× weekly
- Cycle Interval: Optional 2-week pause
- Goal / Description: For basic metabolic modulation studies
Therapeutic Research Protocol
- Dose: 10 – 15 mg (variant 15 mg pen = 100–150 clicks)
- Duration: 24 – 48 weeks
- Frequency: 1× weekly
- Cycle Interval: Repeat after 1 month
- Goal / Description: Modeled on SURPASS/SURMOUNT designs; for long-term metabolic outcomes
Biohacker Microdosing
- Dose: 0.5 – 1 mg every 3 days (variant 5 mg pen = 15–30 clicks / variant 10 mg pen = 5–10 clicks / variant 15 mg pen = 5–10 clicks)
- Duration: 4 – 8 weeks
- Frequency: Every 3 days
- Cycle Interval: Repeat after 1 month
- Goal / Description: Used experimentally to assess mild appetite control and metabolic priming
Maintenance Phase
- Dose: 2.5 – 5 mg (variant 5 mg pen = 76–152 clicks / variant 10 mg pen = 25–50 clicks / variant 15 mg pen = 25–50 clicks)
- Duration: Variable
- Frequency: 1× weekly
- Cycle Interval: Continuous
- Goal / Description: Sustain achieved body composition and metabolic balance.
5-Amino-1MQ
Standard Research Protocol
- Dose: 5 – 10 mg daily (= 15–30 clicks)
- Duration: 2 – 4 weeks
- Frequency: Daily
- Cycle Interval: 2-week pause
- Goal / Description: For baseline NAD+ and fat metabolism studies.
Therapeutic Research Protocol
- Dose: 10 – 20 mg (= 30–61 clicks)
- Duration: 4 – 6 weeks
- Frequency: Daily
- Cycle Interval: 4-week interval
- Goal / Description: Modeled on extended NNMT inhibition protocols in DIO models.
Biohacker Microdosing
- Dose: 2.5 – 5 mg (= 8–15 clicks)
- Duration: 4 weeks
- Frequency: Every other day
- Cycle Interval: Repeat monthly
- Goal / Description: Evaluates mild NAD+ upregulation and metabolic activation.
Mitochondrial Stack Protocol
- Dose: 5 mg 5-Amino-1MQ + 100 mg NAD+ (= 15 clicks)
- Duration: 4 weeks
- Frequency: 3× per week
- Cycle Interval: Repeatable
- Goal / Description: Synergistic design to study combined mitochondrial enhancement.
Slu-pp-332 Capsules
Slu-PP-332 Capsules supply 300 mcg per capsule (bottles of 30 or 60), dosed in whole-capsule increments and taken orally with water.
Standard Research Protocol
- Dose: 300 mcg (1 capsule)
- Duration: 4 – 8 weeks
- Frequency: 1 capsule once daily, with water
- Cycle Interval: 2 – 4 weeks off before repeating
- Goal / Description: Baseline protocol for metabolic and mitochondrial research models.
Therapeutic Research Protocol
- Dose: 300 – 600 mcg (1 – 2 capsules)
- Duration: 6 – 10 weeks
- Frequency: Once daily, preferably before physical-activity windows
- Cycle Interval: 3 – 4 weeks off before repeating
- Goal / Description: Used in research targeting endurance, fat oxidation, and ERR pathway activation.
Biohacker Protocol (experimental)
- Dose: 300 mcg (1 capsule)
- Duration: 8 – 12 weeks
- Frequency: 1 capsule daily, continuous low-dose exposure
- Cycle Interval: 4 weeks off after each cycle
- Goal / Description: Explored for sustained mitochondrial biogenesis and metabolic adaptation in long-term models.
Possible Side Effects
This bundle combines multiple research compounds; the per-compound safety notes below apply. For laboratory research use only – not for human consumption.
GLP-2T
Tіrzеpаtіdе may cause mild and transient gastrointestinal symptoms in some research subjects.
The most common reactions include nausea, diarrhea, and reduced appetite, particularly during initial exposure. Occasional reports include constipation, vomiting, or abdominal discomfort, typically resolving as tolerance develops. Other possible effects include fatigue or transient increases in heart rate during activity.
All effects are reversible and dose-dependent. Proper titration minimizes occurrence.
5-Amino-1MQ
5-Amino-1MQ is generally well tolerated in preclinical studies.
Potential mild effects observed in animal and in vitro models include transient fatigue, mild nausea, or digestive discomfort related to metabolic acceleration.
High doses may cause temporary headaches due to increased NAD+ turnover and mitochondrial activity.
Localized redness or irritation may occur at the subcutaneous injection site.
All effects are dose-dependent and typically resolve after dosage adjustment.
Slu-pp-332 Capsules
Slu-PP-332 is a relatively new research compound, and its safety profile has been characterised only in preclinical settings. In the rodent studies reported to date it has generally been described as tolerated across the dose ranges examined, but comprehensive controlled human safety data do not exist, so conclusions about tolerability in people remain unconfirmed.
Because the compound acts on receptors central to energy metabolism, researchers note that its effects on metabolic and cardiovascular parameters are still being investigated. As with any investigational substance, unknown or idiosyncratic responses cannot be excluded, and the long-term safety of Slu-PP-332 has not been formally established.
This product is intended strictly for laboratory and research use. It is not a medicine, is not intended for human or veterinary consumption, and must be handled only by qualified personnel following appropriate safety practices.
Product Attributes
Scientific References
GLP-2T
- Tіrzеpаtіdе once weekly for the treatment of obesity Human RCT
- Tіrzеpаtіdе : a systematic update Review
- Tіrzеpаtіdе versus sеmаglutіdе once weekly in patients with type 2 diabetes Human RCT
- Efficacy and safety of once-weekly tіrzеpаtіdе versus once-daily insulin degludec as add-on to metformin in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial Human RCT
- Dual GIP and GLP-1 receptor agonist Tіrzеpаtіdе improves beta-cell function and insulin sensitivity in type 2 diabetes Human observational
- Effects of novel dual GIP and GLP-1 receptor agonist tіrzеpаtіdе on biomarkers of inflammation and cardiovascular risk in patients with type 2 diabetes Human RCT
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept Animal
- A long-term safety study of tіrzеpаtіdе (LY3298176) in participants with type 2 diabetes Human RCT
- Effect of tіrzеpаtіdе versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Human RCT
- Once-weekly sеmаglutіdе in adolescents with obesity (comparative to tіrzеpаtіdе context) Human RCT
5-Amino-1MQ
- Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice Animal
- Roles of nicotinamide N-methyltransferase in obesity and type 2 diabetes mellitus Review
- What is 5-Amino-1MQ? uses & benefits of this special peptide Web
- 5-Amino-1MQ for beginners: dosage, benefits, and peptide stacks explained In vitro
- Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice Animal
- 5-Amino-1MQ Animal
- 5-Amino-1MQ vs. sеmаglutіdе: which is better for weight loss? Review
- 5-Amino-1MQ vs sеmаglutіdе: how they differ in weight loss approaches Review
- How 5-Amino-1MQ supports fat burn and metabolic health Web
- New insights on muscle strength: the role of inhibiting an enzyme that hinders NAD synthesis Animal
Slu-pp-332 Capsules
- Billon C, Sitaula S, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023.
- Billon C, Schoepke E, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024.
- Billon C, Appourchaux K, et al. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. J Pharmacol Exp Ther. 2026.
- Audet-Walsh É, Giguère V. The multiple universes of estrogen-related receptor α and γ in metabolic control and related diseases. Acta Pharmacol Sin. 2015.
References are provided for research orientation only and describe preclinical or experimental work.
Included In The Box
Every product arrives in a premium, custom-designed PEPTIDE.Power box, engineered for convenience, hygiene, and safe storage in your refrigerator. Inside, you will find everything needed for your full research protocol:
- 1× Disposable Pre-Mixed Injection Pen
- Powered by our proprietary PSM Technology™ – precision stabilization & mixing system for consistent potency
- 10× Ultra-thin Needles (33G, 4 mm)
- 10× Alcohol Pads for sterile preparation
- Internal Stabilizing Foam Insert to prevent shaking during transport
- Instruction Panel printed on the inside of the box for quick reference
- Security Seal Sticker ensuring the package has not been opened or tampered with
Storage
Store the product in a refrigerator at 1 – 8°C immediately upon delivery. To maintain optimal stability, keep the pen away from light, and do not expose it to repeated temperature changes.
Once reconstituted (all our pens come pre-mixed), research compounds remain stable for 6 – 8 weeks under proper refrigeration.
Do not freeze after reconstitution. Always keep the box closed so the pen, needles, and alcohol pads stay clean and protected.
For best results, use the product consistently within the recommended time window and always follow your research protocol.
Delivery
We ship with Next-Day EU Delivery via DHL Express or UPS Express.
All orders are prepared fresh on the day of dispatch, placed in EPS Cold-Chain Transport Boxes, and shipped with cooling elements to maintain a stable temperature throughout the journey.
Our logistics process is designed so the package arrives overnight, avoiding customs delays inside the European Union.
Products are shipped from our EU facility, ensuring no import duties, no customs clearance, and always fast and secure delivery.
Payment
Due to the nature of research peptides and the high-risk category assigned by payment processors, credit card companies do not generally support merchants in this field.
For this reason, we accept mainly Bank Transfers.
We also work with a crypto payment provider, and from time to time, card payments may be available depending on processor availability.
Within the European Union, SEPA transfers are fast, low-cost, and usually arrive within minutes to a few hours, making the payment process smooth and simple.
Once the transfer is received, your order is prepared immediately and dispatched the same day, depending on the daily cut-off time.
Please note that we do not dispatch shipments on Fridays or on days before official public holidays. This is done to ensure that parcels can be delivered on the next working day and are not held in transit over weekends or holidays.
This method ensures compliance, security, and continuity of service for all customers across the EU.
Didn't find the answer to your question?
View all frequently asked questions
